Consistently, PPARδ agonist GW501516 increased cholesterol levels, whereas its antagonist GSK3787 decreased cholesterol levels in liver CSCs from HCC samples (Fig. 4g). The gene discussed is PPARD; the disease is hepatocellular carcinoma.